164 related articles for article (PubMed ID: 23118116)
1. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement.
Smith V; Piette Y; van Praet JT; Decuman S; Deschepper E; Elewaut D; De Keyser F
J Rheumatol; 2013 Jan; 40(1):52-7. PubMed ID: 23118116
[TBL] [Abstract][Full Text] [Related]
2. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.
Melsens K; Vandecasteele E; Deschepper E; Badot V; Blockmans D; Brusselle G; De Langhe E; De Pauw M; Debusschere C; Decuman S; Deroo L; Houssiau F; Lenaerts J; Piette Y; Thevissen K; Vanthuyne M; Westhovens R; Wijnant S; De Keyser F; Smith V
Acta Clin Belg; 2018 Apr; 73(2):119-125. PubMed ID: 28891418
[TBL] [Abstract][Full Text] [Related]
3. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
[TBL] [Abstract][Full Text] [Related]
4. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.
Smith V; Van Praet JT; Vandooren B; Van der Cruyssen B; Naeyaert JM; Decuman S; Elewaut D; De Keyser F
Ann Rheum Dis; 2010 Jan; 69(1):193-7. PubMed ID: 19103636
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
McQueen FM; Solanki K
Rheumatology (Oxford); 2015 May; 54(5):757-67. PubMed ID: 25573841
[TBL] [Abstract][Full Text] [Related]
7. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
8. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
[TBL] [Abstract][Full Text] [Related]
10. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
Lafyatis R; Kissin E; York M; Farina G; Viger K; Fritzler MJ; Merkel PA; Simms RW
Arthritis Rheum; 2009 Feb; 60(2):578-83. PubMed ID: 19180481
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in psoriatic arthritis: an exploratory evaluation.
Jimenez-Boj E; Stamm TA; Sadlonova M; Rovensky J; Raffayová H; Leeb B; Machold KP; Graninger WB; Smolen JS
Ann Rheum Dis; 2012 Nov; 71(11):1868-71. PubMed ID: 22833373
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
14. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
Valentini G; Paone C; La Montagna G; Chiarolanza I; Menegozzo M; Colutta E; Ruocco L
Scand J Rheumatol; 2006; 35(1):35-8. PubMed ID: 16467039
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
[TBL] [Abstract][Full Text] [Related]
18. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
20. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]